Today's Pre-Market Stock Movers: DWAC, BBBY, ILMN, DBX and More

• $United Microelectronics(UMC.US)$ +0.8% (August revs)

• $ChannelAdvisor(ECOM.US)$ +54.4% (to be acquired for $23.10 per share)

• $IVERIC bio(ISEE.US)$ +42.3% (topline data from Zimura GATHER2 phase 3 clinical trialingeographic atrophy)

• $Monte Rosa Therapeutics(GLUE.US)$ +10% (receives FDA clearance of Investigational New Drug Application for MRT-2359)

• $IDEAYA Biosciences(IDYA.US)$ +4.9% (reports first-patient-in for Phase I clinical trial to evaluate darovasertib monotherapy)

• $Leap Therapeutics(LPTX.US)$ +4% (New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress)

• $MannKind(MNKD.US)$ +2.9% (completes phase 1 study of inhaled clofazimine)

• $Athira(ATHA.US)$ +2.8% (update to its plans for the ongoing LIFT-AD clinical trial of fosgonimeton)

• $Pacific Airport(PAC.US)$ +2.7% (August traffic)

• $The Timken(TKR.US)$ +2.5% (to acquire GGB Bearing Technology, expanding its engineered bearing portfolio with complementary products)

• $Hut 8(HUT.US)$ +2.1% (production and operations update for August 2022)

• $Dropbox(DBX.US)$ +1.7% (Bank of America initiated coverage of the file storing and sharing service with a buy rating, saying strong free cash flow generation should be attractive to shareholders.)

• $Ironwood Pharmaceuticals(IRWD.US)$ +1.3% (topline data from a PhaseIIIclinical trial evaluating LINZESS 72 mcg)

• $Kingsoft Cloud(KC.US)$ -5.6%

• $Alvotech(ALVO.US)$ -6.3% (Update on Initial AVT02 Biologies License Application; also downgraded to Sell from Buy at Citigroup)

• $Zymeworks(ZYME.US)$ -4.9% (Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers)

• $Apexigen(APGN.US)$ -1.5% (New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022)

• $Church & Dwight(CHD.US)$ -1.4% (signed a definitive agreement to acquire the Hero Mighty Patch brand and other acne treatment products for $630 mln, consisting of cash and Church & Dwight restricted stock)